Organoids in Drug Discovery
Predictive methods are needed to increase the chance of success in your drug programs before clinical trials. Organoids are a beneficial tool in drug discovery and toxicity testing, aiding target discovery, validation, and pre-clinical testing. Organoid models provide a more physiologically relevant cellular composition and tissue structure than standard 2D models, with increased accuracy and higher throughput. Additionally, patient-derived organoids can be used to predict drug toxicity and efficacy, allowing you to make precise and confident decisions to advance your drug candidates.
Learn how organoids can help your drug-discovery workflow below.
Interview: The Role of Organoids and Organ-On-A-Chip Systems in Drug Discovery
Drs Bas Trietsch, Chief Technology Officer at MIMETAS, and Jenna Moccia, Director of Product Management at ϳԹ, discuss the challenges that lead pharma companies to adopt advanced in vitro models, such as organoids and organ-on-a-chip, and the benefits they see after incorporating these systems in their research.
Watch Now >-
How to Co-Culture Human Pluripotent Stem Cell (hPSC)-Derived Forebrain Neurons and AstrocytesUse this optimized protocol to combine these cell types in 2D after generating each of them separate -
CRISPR-Cas9 Genome Editing of Human Intestinal OrganoidsCRISPR-Cas9 genome editing of intestinal organoids cultured in IntestiCult™ Organoid Growth Medium (Human) (Catalog #06010) using the ArciTect™ CRISPR-Cas9 ribonucleoprotein (RNP)-based system and ϳԹ's Guide RNA Design Tool -
Applications of Human Intestinal Organoid Cultures in Drug DiscoveryHuman intestinal organoids provide a scalable and highly predictive model system for studying the effects of novel therapeutics in vitro. Intestinal organoids contain the relevant cell types that constitute the intestinal epithelium and, as such, can be maintained in various states of proliferation or differentiation. These physiologically relevant models reveal the toxicity of compounds that can not be seen in Caco-2 cells, which are frequently used to model the intestine during drug development programs. <br><br>In this webinar, Danny Leung and Dr. Victoria Conlin from ϳԹ describe, in detail, what intestinal organoids are, how they mimic the immunocytochemistry and morphology of the human gut epithelium, and how to use organoids for drug screening. They also discuss the intestinal organoid assays offered by Contract Assay Services (CAS) at ϳԹ.
